Q-omics provides the consensus-scored EXOSC3 profile across patient tissues and cancer cell-line models. EXOSC3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EXOSC3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, EXOSC3 protein abundance shows 31,413 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where EXOSC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXOSC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXOSC3 survival associations across molecular data types. EXOSC3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXOSC3 RNA expression–survival associations across cancer types. High EXOSC3 expression shows unfavorable associations in KIRP, ACC, LIHC, UVM and LGG, but favorable associations in OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EXOSC3 RNA expression.
This table summarizes EXOSC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for EXOSC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXOSC3 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, LIHC, HNSC and LUSC. The COAD box plot shows higher EXOSC3 RNA expression in tumor versus normal tissue (log2 FC = +1.267, t-test p < 0.001).
This table shows molecular features associated with EXOSC3 in patient tissues and cancer cell lines. In patient samples, EXOSC3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EXOSC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
